10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

Authors: Courtney D. DiNardo, Abhishek Maiti, Caitlin R. Rausch, Naveen Pemmaraju, Kiran Naqvi, Naval Daver, Tapan M. Kadia, Gautam Borthakur, Maro Ohanian, Yesid Alvarado, Ghayas C. Issa, Guillermo Montalban‐Bravo, Nicholas J. Short, Musa Yılmaz, Prithviraj Bose, Elias Jabbour, Koichi Takahashi, Jan A. Burger, Guillermo Garcia‐Manero, Nitin Jain, Steven M. Kornblau, Philip A. Thompson, Zeev Estrov, Lucia Masárová, Koji Sasaki, Srđan Verstovšek, Alessandra Ferrajoli, William Weirda, Sa A. Wang, Sergej Konoplev, Zhining Chen, Sherry Pierce, Jing Ning, Wei Qiao, Farhad Ravandi, Michael Andreeff, John S. Welch, Hagop M. Kantarjian, Marina Konopleva - The Lancet 2020 cited by 331